HUE045936T2 - Clostridium difficile immunogén készítmény - Google Patents

Clostridium difficile immunogén készítmény

Info

Publication number
HUE045936T2
HUE045936T2 HUE15733404A HUE15733404A HUE045936T2 HU E045936 T2 HUE045936 T2 HU E045936T2 HU E15733404 A HUE15733404 A HU E15733404A HU E15733404 A HUE15733404 A HU E15733404A HU E045936 T2 HUE045936 T2 HU E045936T2
Authority
HU
Hungary
Prior art keywords
clostridium difficile
immunogenic preparation
immunogenic
preparation
difficile
Prior art date
Application number
HUE15733404A
Other languages
English (en)
Hungarian (hu)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HUE045936T2 publication Critical patent/HUE045936T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE15733404A 2014-06-25 2015-06-25 Clostridium difficile immunogén készítmény HUE045936T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition

Publications (1)

Publication Number Publication Date
HUE045936T2 true HUE045936T2 (hu) 2020-01-28

Family

ID=53498986

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15733404A HUE045936T2 (hu) 2014-06-25 2015-06-25 Clostridium difficile immunogén készítmény

Country Status (17)

Country Link
US (1) US20170218031A1 (enExample)
EP (2) EP3160500B1 (enExample)
JP (2) JP6688233B2 (enExample)
CN (1) CN106536544B (enExample)
BE (1) BE1022949B1 (enExample)
BR (1) BR112016030096B1 (enExample)
CY (1) CY1122145T1 (enExample)
DK (1) DK3160500T3 (enExample)
ES (1) ES2749701T3 (enExample)
HR (1) HRP20191864T1 (enExample)
HU (1) HUE045936T2 (enExample)
LT (1) LT3160500T (enExample)
MX (1) MX374380B (enExample)
PL (1) PL3160500T3 (enExample)
PT (1) PT3160500T (enExample)
SI (1) SI3160500T1 (enExample)
WO (1) WO2015197737A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691609B (zh) * 2017-03-15 2024-04-19 诺瓦瓦克斯股份有限公司 用于诱导针对艰难梭菌的免疫应答的方法和组合物
CA3102353A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
JP2002514886A (ja) 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
EP1169456B1 (en) * 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2005004791A2 (en) * 2002-11-08 2005-01-20 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
AU2012349753A1 (en) * 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
PL3160500T3 (pl) 2020-02-28
CN106536544A (zh) 2017-03-22
BR112016030096A8 (pt) 2021-07-06
PT3160500T (pt) 2019-11-11
HRP20191864T1 (hr) 2020-01-10
EP3636278A2 (en) 2020-04-15
CA2952118A1 (en) 2015-12-30
EP3160500A1 (en) 2017-05-03
EP3160500B1 (en) 2019-08-21
DK3160500T3 (da) 2019-11-11
JP2017520573A (ja) 2017-07-27
BE1022949A1 (fr) 2016-10-21
US20170218031A1 (en) 2017-08-03
SI3160500T1 (sl) 2019-11-29
CY1122145T1 (el) 2020-11-25
LT3160500T (lt) 2019-10-25
MX374380B (es) 2025-03-06
EP3636278A3 (en) 2020-07-15
MX2016017094A (es) 2017-05-03
WO2015197737A1 (en) 2015-12-30
CN106536544B (zh) 2020-04-07
BE1022949B1 (fr) 2016-10-21
BR112016030096A2 (pt) 2017-08-22
JP6688233B2 (ja) 2020-04-28
JP2020100625A (ja) 2020-07-02
BR112016030096B1 (pt) 2023-10-03
ES2749701T3 (es) 2020-03-23

Similar Documents

Publication Publication Date Title
DK3146065T3 (da) Methods and compositions for reducing clostridium difficile infection
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3171891T3 (da) Fremgangsmåde
DK3262071T3 (da) Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
DK3218504T3 (da) Trisegmenterede arenavira som vaccinevektorer
LT3536380T (lt) Greitai veikiančios insulino kompozicijos
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
HUE047041T2 (hu) Eljárás poliéteraminok elõállítására
DK3132009T3 (da) Fremgangsmåde
IL248223A0 (en) Vaccine compositions
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3233161T3 (da) Kanylegrænseflade
DK3578179T3 (da) Process for the preparation of cyclic depsipeptides
HUE048790T2 (hu) Vizes készítmény
DK3148513T3 (da) Ceritinib-formulering
EP3181125C0 (en) CAPSULE FORMULATION
FR3024647B1 (fr) Transat de puericulture
DK3160500T3 (da) Clostridium difficile immunogen sammensætning
HUE047581T2 (hu) Készítmény
DK3193856T3 (da) Formulering
FR3026387B1 (fr) Carenage de rotor, rotor et aeronef
IL249130B (en) Preparation of piperidine-4-carbothioamide
LT3188755T (lt) Vakcina
DK3183264T3 (da) Pegyleringsfremgangsmåde
CU20140011S4 (es) Juego de sillas combinadas